Status:
TERMINATED
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor
Lead Sponsor:
Northwell Health
Conditions:
Focal Segmental Glomerulosclerosis
Eligibility:
All Genders
2-60 years
Phase:
PHASE1
Brief Summary
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability...
Detailed Description
Patients with resistant FSGS have persistent proteinuria and a high risk of progression to end stage kidney disease (ESKD). A circulating factor that increases glomerular permeability to albumin (Palb...
Eligibility Criteria
Inclusion
- Primary FSGS
- Resistance to steroids and another immunosuppressive medication
Exclusion
- Secondary FSGS
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00816478
Start Date
December 1 2008
End Date
December 1 2009
Last Update
September 10 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.